Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
PDC platform represents a drug delivery platform enabling intracellular payload delivery to tumor cells.
|
$11.01M |
$3.42
+11.56%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$10.00M |
$1.05
-3.21%
|
|
SCNX
Scienture Holdings, Inc.
SCNX emphasizes novel formulations and delivery platforms (drug delivery platforms) as a competitive edge.
|
$9.55M |
$0.59
-1.05%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt's Boltbody ISAC platform is a drug-delivery platform designed to deliver immune-stimulating payloads via antibodies.
|
$9.50M |
$5.08
+0.30%
|
|
MBRX
Moleculin Biotech, Inc.
MBRX utilizes liposomal drug delivery formulations for Annamycin, aligning with Drug Delivery Platforms as a major capability.
|
$8.48M |
$0.28
-23.39%
|
|
IMNN
Imunon, Inc.
TheraPlas is a drug delivery platform enabling loco-regional cytokine production.
|
$8.46M |
$3.94
+3.68%
|
|
BCDA
BioCardia, Inc.
Helix is BioCardia's proprietary transendocardial biotherapeutic delivery system, a core drug-delivery platform the company uses to administer its cell therapies.
|
$8.30M |
$1.43
-0.35%
|
|
RNAZ
TransCode Therapeutics, Inc.
TTX is a proprietary drug delivery platform for RNA therapeutics, enabling tumor targeting and intracellular delivery.
|
$7.69M |
$9.30
+1.25%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Drug Delivery Platforms are at the core of RedTail/NeuroNova/SuperNova, enabling systemic delivery of therapeutic payloads to tumors.
|
$7.07M |
$1.49
+6.43%
|
|
PHIO
Phio Pharmaceuticals Corp.
INTASYL is described as a self-delivering drug delivery platform for gene silencing.
|
$7.04M |
$1.24
+3.33%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
ImmCelz/AlloStem platform could be considered a Drug Delivery Platform for cell therapies.
|
$6.89M |
$2.67
-2.55%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$6.56M |
$4.71
-18.60%
|
|
ALZN
Alzamend Neuro, Inc.
AL001 uses a patented ionic cocrystal drug-delivery platform to improve brain lithium delivery.
|
$6.49M |
$2.25
+4.91%
|
|
KALA
KALA BIO, Inc.
MSC-S platform represents a drug delivery platform for cell-free therapies.
|
$6.39M |
$0.94
+47.19%
|
|
SNGX
Soligenix, Inc.
Multiple proprietary platforms (HyBryte PDT, IDR, ThermoVax) represent drug delivery platforms.
|
$6.30M |
$1.48
+4.61%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$5.76M |
$3.56
+23.61%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$5.65M |
$0.84
-5.92%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Invisicare-based drug-delivery platform is used for QRX003 and other topical formulations, constituting a major product/technology platform.
|
$5.23M |
$20.87
-6.41%
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is delivered via a capsule-based drug delivery approach; tag Drug Delivery Platforms captures the delivery modality as a core product attribute.
|
$4.51M |
$2.85
+2.33%
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$4.23M |
$0.46
+5.42%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.76M |
$0.94
-0.04%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.94M |
$0.59
-0.90%
|
|
BICX
BioCorRx Inc.
BICX104 comprises a biodegradable, sustained-release naltrexone implant, representing a drug-delivery platform.
|
$2.18M |
$0.40
|
|
REVB
Revelation Biosciences, Inc.
Gemini is a drug-delivery platform formulation used across multiple indications, matching Drug Delivery Platforms.
|
$1.59M |
$0.93
+10.81%
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The company references a proprietary platform designed to enhance drug delivery for radiation sensitization, indicating a drug delivery platform.
|
$1.45M |
$1.36
+2.26%
|
|
NLSP
NLS Pharmaceutics AG
The company relies on proprietary drug-delivery platforms (extended-release mazindol formulation and DOXA platform) to optimize therapeutic profiles.
|
$377531 |
$0.79
-74.81%
|
|
LADX
LadRx Corporation
LADR is a proprietary drug delivery platform used to target tumors and release payloads.
|
$64362 |
$0.13
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$8442 |
$0.52
-11.07%
|
|
NCNA
NuCana plc
ProTide is a proprietary drug-delivery platform used to enhance efficacy/safety of nucleoside analogs, a core differentiator for NuCana.
|
N/A |
$3.97
+3.12%
|
Showing page 3 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
